Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.

Type
Private
HQ
San Francisco, US
Founded
2013

Alector Locations

San Francisco, US

Alector Metrics

Alector Summary

Founding Date

2013

Total Funding

$61.5 M

Latest funding size

$29.5 M

Time since last funding

11 months

Investors

Alector Company Life

You may also be interested in